ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentObfeldenEVIIVE AG
EVIIVE AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

EVIIVE AG develops blood-based liquid biopsy diagnostics to support the selection of immunotherapies in oncology. The company researches and builds extracellular vesicle (EV) biomarker platforms, including IMPASS and IMPACT, to profile cell-type specific EV signals and stratify patients for treatment.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
3.8/5

EVIIVE AG

✓ Offered8
Biomarker Discovery Platform
Next-generation biomarker discovery platform for precise diagnostics in immuno-oncology; analysis of extracellular vesicles, treatment selection, response prediction and longitudinal monitoring.
Blood-based Diagnostics
Blood-based diagnostics from small plasma volumes with high-dimensional analysis of extracellular vesicles for non-invasive, clinically relevant insights into immune and tumor signals.
Immuno-Oncology Tests for Treatment Selection and Response Prediction
Diagnostic tests for early patient selection in immuno-oncology; prediction of therapy response, stratification of patient groups and support for treatment decisions.
Companion Diagnostics
Development of companion diagnostics for oncology immunotherapies; support for clinical decisions, patient selection and translational development.
EV Profiling
Profiling of extracellular vesicles to capture dynamic immune, tumor and metabolic interactions; analysis of EV subpopulations from blood samples.
Immune Profiling and Stratification
High-dimensional immune profiling from blood to identify patient subgroups by immune activity, treatment response and biomarker expression.
Multi-omics Analysis
Multi-omics analysis of RNA, DNA and proteomics to elucidate molecular signatures, resistance pathways and therapeutic target structures.
Research and Development Platform for Immuno-Oncology
Research platform for preclinical and translationally oriented EV biomarkers in cancer diagnostics and personalized immunotherapy.
Trust & reputation

ranQ Trust Score of EVIIVE AG: 3.8 out of 5.0

Trust Score3.8/ 5.0

High

x

Data basis 58% · As of October 2026

EVIIVE AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
EVIIVE AG scores 59.7 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.39.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
EVIIVE AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
EVIIVE AG scores 26.7 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.40.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.13.34%
Qualifications+0.00

EVIIVE AG reaches a ranQ Trust Score of 3.8 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

February 28, 2025Media
Eviive forscht erfolgreich in der Krebsdiagnostik und -behandlung
affolteranzeiger.ch
December 27, 2024Media
CHF 150,000 from Venture Kick to bring precision diagnostics to cancer immunotherapies
startupticker.ch

Knowledge

No knowledge articles yet

Once EVIIVE AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

EVIIVE AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank EVIIVE AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of EVIIVE AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Mühlestrasse 4b
8912 Obfelden

At a glance

Legal form
Corporation
UID
CHE-250.572.156
Founded
2024 · 2 years
Last commercial register change
December 4, 2024
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    YG
    YugaCell GmbH
    Zurich
    IB
    Inthera Bioscience AG
    Zurich
    PA
    Philochem AG
    Otelfingen
    DL
    DAiNA Laboratories AG
    Schlieren
    MA
    Mabylon AG
    Schlieren
    SA
    Stuvel Advisory
    Zurich
    NM
    NanoFLOWCELL Management AG
    Kilchberg Zh
    EE
    Eagle Eye Solutions GmbH
    Meilen